Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosed with advanced hematologic malignancies meeting the following criteria:~  * Multiple myeloma~    * Received ≥ 2 lines of prior chemotherapy (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy)~ * Acute myeloid leukemia~ * Acute lymphoblastic leukemia~ * Diffuse large B-cell lymphoma~ * Hodgkin lymphoma~ * Mantle cell lymphoma~ * Mature T- and NK-cell neoplasms restricted to the following WHO-defined entities:~    * T-cell prolymphocytic leukemia~   * T-cell large granular lymphocytic leukemia~   * Aggressive NK-cell leukemia~   * Adult T-cell leukemia/lymphoma~   * Extranodal NK/T-cell lymphoma (nasal type)~   * Mycosis fungoides~   * Sézary syndrome~   * Primary CD30-positive T-cell lymphoproliferative disorders~   * Primary cutaneous anaplastic large cell lymphoma~   * Primary cutaneous gamma-delta T-cell lymphoma~   * Peripheral T-cell lymphoma (not otherwise specified)~   * Angioimmunoblastic T-cell lymphoma~   * Anaplastic large cell lymphoma (ALK-positive/ALK-negative)~ * Grade 3B follicular lymphoma~* Relapsed following or progressed during standard therapy~* Meeting the following criteria:~  * Standard intensive therapy is not feasible~ * Current disease state for which there is no standard effective therapy~ * Refused standard therapy where no curative option exists~* Measurable disease, defined as the following:~  * Myeloma: measurable serum monoclonal protein \> 1 g/dL for IgG, or \> 0.5 g/dL for IgA, IgM or IgD, or difference between involved and uninvolved free light chain levels in serum \> 100 mg/L~ * Lymphoma: must have ≥ 1 lesion measurable by CT (longest diameter ≥ 15 mm)~ * Acute leukemia: ≥ 20% blasts in bone marrow or in peripheral blood (≥ 200/mL blasts in peripheral blood)~* No HIV-associated lymphoma~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 75,000/mm³ (if bone marrow impairment, ≥ 20,000/mm\^3)~* Hemoglobin \> 80 g/L (if considered to be caused by the underlying hematologic malignancy or bone marrow impairment, \> 80 g/L after transfusion)~* Bilirubin ≤ 1.5 times upper limit of normal (ULN) (if suspected hemolysis, direct bilirubin ≤ 1.5 times ULN)~* ALT ≤ 2.5 times ULN~* Calculated creatinine clearance \> 30 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after completion of study treatment~* Willing and capable to comply with an oral regimen~* Capable of understanding information given by the investigator on the trial~* Able to adhere and remain in geographic proximity to allow proper staging, treatment, and followup~* No other non-hematologic malignancy within the past 5 years, except adequately treated cervical carcinoma in situ or localized nonmelanoma skin cancer~* No known chronic hepatitis B or C infection or known HIV infection~* No serious underlying medical condition (at the judgment of the investigator) which would impair the ability of the patient to participate in the trial, including any of the following:~  * Active autoimmune disease~ * Uncontrolled diabetes~ * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric disorder~* No myocardial infarction within the past 6 months~* No polyneuropathy \> grade 1 significantly interfering with activities of daily living or painful polyneuropathy~* No known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No more than 4 prior lines of chemotherapeutic regimens (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy)~* More than 30 days since prior treatment in a clinical trial~* More than 30 days since prior and no concurrent chemotherapy or biologic agents~  * For patients with acute leukemia, hydroxyurea may be given up to 48 hours before first administration of the trial treatment, and low dose cytarabine (up to 20 mg/m\^2) and mitoxantrone up to 20 mg up to 14 days before first dosing~* At least 1 week since prior and no concurrent CYP3A4 modulators~* No concurrent other experimental drugs~* No concurrent radiotherapy~* No concurrent antineoplastic therapy with chemotherapeutic or biologic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bortezomib + nelfinavir (Type: EXPERIMENTAL): escalation 3 by 3 cohorts

Based on this trial design, predict the completion outcome and termination type (if applicable).